Viking Therapeutics, Inc. (VKTX) financial statements (2021 and earlier)

Company profile

Business Address 12340 EL CAMINO REAL, SUITE 250
SAN DIEGO, CA 92130
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments248276302211314
Cash and cash equivalents29825931
Short-term investments219267277121013
Other undisclosed current assets881111
Total current assets:256284302221415
Noncurrent Assets
Operating lease, right-of-use asset01
Deposits noncurrent assets000 00
Deferred costs     0
Other undisclosed noncurrent assets00001 
Total noncurrent assets:010010
TOTAL ASSETS:257284302221515
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1265422
Accounts payable421211
Accrued liabilities844211
Interest and dividends payable   00 
Debt 0 33 
Other undisclosed current liabilities0  11 
Total current liabilities:1275962
Noncurrent Liabilities
Long-term debt and lease obligation00   2
Long-term debt, excluding current maturities     2
Operating lease, liability00
Liabilities, other than long-term debt  0 00
Deferred revenue and credits 00
Deferred rent credit  0
Other undisclosed noncurrent liabilities(0)    3
Total noncurrent liabilities:000 05
Total liabilities:1275967
Stockholders' equity
Stockholders' equity attributable to parent2442772981389
Common stock000000
Additional paid in capital413406401946854
Accumulated other comprehensive income (loss)(0)0(0)(0)(0)(0)
Accumulated deficit(168)(129)(103)(81)(60)(46)
Total stockholders' equity:2442772981389
TOTAL LIABILITIES AND EQUITY:257284302221515

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Gain (loss) on disposition of assets for financial service operations00(0)
Gross profit:00    
Operating expenses(43)(33)(26)(19)(14)(12)
Other undisclosed operating income (loss)(0)(0)0   
Operating loss:(43)(33)(26)(19)(14)(12)
Nonoperating income (expense)(1)64(2)(1)(11)
Investment income, nonoperating(4)(0)(0)   
Other nonoperating income (expense)374(2)(1)(11)
Loss from continuing operations before income taxes:(43)(26)(22)(21)(15)(23)
Income tax benefit1389   
Loss before gain (loss) on sale of properties:(31)(18)(13)(21)(15)(23)
Other undisclosed net loss(9)(7)(9)   
Net loss available to common stockholders, diluted:(39)(26)(22)(21)(15)(23)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(39)(26)(22)(21)(15)(23)
Comprehensive loss:(39)(26)(22)(21)(15)(23)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0(0)(0)0(0)
Comprehensive loss, net of tax, attributable to parent:(40)(25)(22)(21)(15)(23)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: